OncoSec Medical Inc. (OTCQB: ONCS),
a company developing its ImmunoPulse DNA-based intratumoral cancer
immunotherapy, announces that several company representatives will
present at the International
Society of DNA Vaccines (ISDV) 2014 DNA Vaccine Conference, being
held July 21-23, 2014 at the Westin San Diego Gaslamp Quarter Hotel in
San Diego, CA.
As a Chairman's Cup Sponsor for the event, OncoSec will be prominently
featured during the conference. Speakers will include Robert Pierce,
M.D., Chief Medical Officer, Soldano Ferrone, M.D., Ph.D., Scientific
Advisory Board member, Richard Heller, Ph.D., Scientific Advisory Board
member, and Holbrook Kohrt, M.D., Ph.D., clinical investigator.
Many of the leading investigators in cancer immunotherapy will be
attending to discuss the latest research in immune-modulating
antibodies, engineered T cells, gene delivery methods and combination
approaches in immunotherapy. This year, several presentations will touch
upon electroporation and its significance as a safe and efficient means
of non-viral gene delivery, and discuss its clinical potential as an
There will also be a spotlight on the emerging field of intratumoral
immunotherapy. Dr. Pierce will lead this session of the conference with
his presentation "Intralesional DNA Immunotherapy: Converting Anti-PD-1
Non-Responders to Responders", as part of the "Tumor Targeting" track.
"We are excited to have Dr. Holbrook Kohrt presenting his work in a talk
entitled Anti-CTLA-4 and CPG: Experience with Direct Lesion Therapy,"
reports Dr. Pierce. "He and his colleagues at Stanford have been
on the forefront of intratumoraltherapy and thanks in part to these
efforts, investigators are beginning to realize the potential of
intratumoral therapies to directly combat the immunosuppressive
mechanisms deployed by tumors. We are witnessing the emergence of a new
vision-one in which the optimal future immunotherapy will combine
intratumoral and systemic approaches."
Punit Dhillon, President and CEO, announced, "We are proud to be a
Chairman's Cup Sponsor for this event. Each year, ISDV's annual DNA
Vaccines conference has become larger and better attended by key thought
leaders in the space, and this year is no different. Including OncoSec,
several of the leading companies in developing electroporation
technology for DNA vaccines and immunotherapy will be presenting and
sharing data, and this year, OncoSec will lead the discussion in the
importance of developing intratumoral immunotherapies using
About the International Society of DNA Vaccines
The International Society of DNA Vaccines is an organization created to
facilitate the advancement of therapeutic and preventive DNA vaccines.
The society is comprised of international scientists and researchers who
have dedicated their careers to improving world health and the
advancement of DNA vaccines and therapies.
About the 2014 DNA Vaccine Conference
DNA Vaccines 2014 is a scientific conference that offers major
opportunities for leading researchers worldwide to gather together and
report on the cutting-edge advances in research in the field of DNA
vaccines, debate accomplishments, and reveal new directions for
translational exploitation. Highlights include scientific plenary
sessions, scientific poster presentations and the attendance and
participation of internationally renowned scientists and researchers.
About OncoSec Medical Inc.
OncoSec Medical Inc. is a biopharmaceutical company developing its
ImmunoPulse immunotherapy to treat solid tumors. OncoSec Medical's core
technology leverages a proprietary electroporation platform to
enhance the local delivery and uptake of DNA IL-12 and other DNA-based
immune-modulating agents. Clinical studies of ImmunoPulse have
demonstrated an acceptable safety profile and preliminary evidence of
anti-tumor activity in the treatment of various skin cancers, as well as
the potential to initiate a systemic immune response without the
systemic toxicities associated with other treatments. OncoSec's clinical
programs currently include three Phase 2 trials targeting metastatic
melanoma, Merkel cell carcinoma and cutaneous T-cell lymphoma, conducted
in collaboration with several prominent academic medical centers. As the
company continues to evaluate ImmunoPulse in these indications, it is
also investigating additional indications and combination therapeutic
approaches. For more information, please visit www.oncosec.com.
This press release contains forward-looking statements within the
meaning of the U.S. Private Securities Litigation Reform Act of 1995.
Any statements in this release that are not historical facts may be
considered such "forward-looking statements." Forward-looking statements
are based on management's current preliminary expectations and are
subject to risks and uncertainties, which may cause our results to
differ materially and adversely from the statements contained herein.
Some of the potential risks and uncertainties that could cause actual
results to differ from those predicted include our ability to raise
additional funding, our ability to acquire, develop or commercialize new
products, uncertainties inherent in pre-clinical studies and clinical
trials, unexpected new data, safety and technical issues, competition,
and market conditions. These and additional risks and uncertainties are
more fully described in OncoSec Medical's filings with the Securities
and Exchange Commission. Undue reliance should not be placed on
forward-looking statements, which speak only as of the date they are
made. OncoSec Medical disclaims any obligation to update any
forward-looking statements to reflect new information, events or
circumstances after the date they are made, or to reflect the occurrence
of unanticipated events.
[ Back To NFVZone's Homepage ]